Forteo to remain Decision Resources' proprietary clinical gold standard for treatment of osteoporosis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a drug's effect on reduction of new hip fractures is the attribute that most influences U.S. and European surveyed primary care physicians' (PCPs') prescribing decisions in osteoporosis. Clinical data and the opinions of interviewed thought leaders indicate Eli Lilly's Forteo (in Europe the brand name is Forsteo) has advantages over patient-share leader alendronate (Merck's Fosamax, Teijin's Bonalon, generics) on this attribute.

The new report entitled Osteoporosis: Prolia Fails to Meet Physicians' Expectations but Retains Blockbuster Potential also finds that Forteo will remain Decision Resources' proprietary clinical gold standard through 2018 for the treatment of osteoporosis. While some drugs in development hold promise, such as Amgen/GlaxoSmithKline's Prolia, most have less favorable efficacy, safety and tolerability attributes compared with Forteo.

"Amgen/GlaxoSmithKline's first-in-class biologic Prolia has not demonstrated sufficient efficacy to surmount Forteo as our clinical gold standard. Physicians continue to seek improved fracture prevention and although Prolia's twice yearly injections offer greater convenience than Forteo, which requires daily injections, Prolia doesn't demonstrate superiority in efficacy," stated Decision Resources Analyst Matthew Scutcher, Ph.D. "Although Prolia will still achieve blockbuster status in the osteoporosis drug market, its uptake will be limited by competition from Forteo and other currently marketed therapies."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Blackcurrant supplements show promise in preventing bone density loss in post-menopausal women